The company Deepull has obtained 13 million euros in a capital increase led by the Innvierte fund and which has had the support of Kurma Partners, Alta Life Sciences, UI and Axis.
The money will be invested in the technological development of a platform that aims to advance the early detection of sepsis. Jordi Carrera, founder of the company together with Rafel Bru, explains that the technology is in the testing phase and that there is still no specific date for its arrival on the market.
"We are processing several patents at an international level, it is a pioneering technology," says Carrera, who has experience in the sector. Along with Bru, this entrepreneur also founded the STAT-Dx company, which was sold to the Qiajen firm in 2018.
Deepull was born in 2020 at the Barcelona Science Park, where it employs a team that will reach 20 people by the end of this year. The company is confident in the fit of technology in the market. The platform aims to detect more than 250 different pathogens, and about 15 resistance genes, in one hour and from 10 ml of blood. The device will be automated so that it can be located in any clinical environment (laboratory, emergency room, ICU).
